Fairvalue-Calculator Fairvalue-Calculator
EN DE

AriBioLab Co (261780) Fair Value & Analysis

Healthcare · KR · Market cap 71.3B KRW

Price2,590 KRW
Fair Value794.57 KRW
Upside-69.3%
Quality95/100
Evidence: Low Range 595.93 KRW – 993.21 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

AriBioLab Co (261780) currently trades at 2,590 KRW, while our model-based Fair Value estimate is 794.57 KRW — implying the stock looks roughly 69.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment. It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster. Additionally, an influenza vaccine for seasonal flu, recombinant MBL for infectious disease suppression, and a TB booster vaccine. The company also develops 3rd-generation Hepatitis B vaccine (CVI HBV 001), a preventive vaccine using 3rd generation recombinant antigens; Hepatitis B therapeutic vaccine (CVI HBV 002), a therapeutic vaccine for treatment of patients and carriers of chronic hepatitis B; Shingles vaccine (CVI VZV 001), for prevention of shingles and postherpetic neuralgia; Next generation flu vaccine, quadrivalent…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is AriBioLab Co (261780) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 794.57 KRW versus a price of 2,590 KRW — about −69% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 261780?
Our 21-model fair value for AriBioLab Co is 794.57 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 2,590 KRW.
What is the quality score of 261780?
AriBioLab Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.